Selected research
Market Structure
Global Hyperthermia Therapy for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Hyperthermia Therapy for Cancer market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Hyperthermia Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Hyperthermia Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Hyperthermia Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Hyperthermia Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Hyperthermia Therapy for Cancer include Pyrexar Medical, Oncotherm, Andromedic, Yamamoto Vinita, Med-Logix, Thermofield, Celsius42, Dongseo Medicare and ThermaSolutions, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Hyperthermia Therapy for Cancer market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Hyperthermia Therapy for Cancer and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Hyperthermia Therapy for Cancer sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hyperthermia Therapy for Cancer market size, projected growth trends, production technologies, key applications, and end-use industries.
Hyperthermia Therapy for Cancer Segment by Company
Pyrexar Medical
Oncotherm
Andromedic
Yamamoto Vinita
Med-Logix
Thermofield
Celsius42
Dongseo Medicare
ThermaSolutions
Verthermia
Combat Medical
Hydrosun
RanD Biotech
Shenzhen ET Medical Technology
Jiangsu Nova Medical Equipment
Hyperthermia Therapy for Cancer Segment by Type
Superficial Hyperthermia
Deep Regional Hyperthermia
Hyperthermia Therapy for Cancer Segment by Application
Breast Cancer
Cervical Cancer
Soft Tissue Sarcoma
Melanoma
Others
Hyperthermia Therapy for Cancer Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hyperthermia Therapy for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hyperthermia Therapy for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hyperthermia Therapy for Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Hyperthermia Therapy for Cancer market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hyperthermia Therapy for Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hyperthermia Therapy for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Hyperthermia Therapy for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Superficial Hyperthermia
- Deep Regional Hyperthermia
Applications
- Breast Cancer
- Cervical Cancer
- Soft Tissue Sarcoma
- Melanoma
- Others
Companies covered
- Pyrexar Medical
- Oncotherm
- Andromedic
- Yamamoto Vinita
- Med-Logix
- Thermofield
- Celsius42
- Dongseo Medicare
- ThermaSolutions
- Verthermia
- Combat Medical
- Hydrosun
- RanD Biotech
- Shenzhen ET Medical Technology
- Jiangsu Nova Medical Equipment
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Hyperthermia Therapy for Cancer Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Hyperthermia Therapy for Cancer Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Hyperthermia Therapy for Cancer Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Hyperthermia Therapy for Cancer Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Hyperthermia Therapy for Cancer Market Dynamics
- 2.1 Hyperthermia Therapy for Cancer Industry Trends
- 2.2 Hyperthermia Therapy for Cancer Industry Drivers
- 2.3 Hyperthermia Therapy for Cancer Industry Opportunities and Challenges
- 2.4 Hyperthermia Therapy for Cancer Industry Restraints
3 Hyperthermia Therapy for Cancer Market by Manufacturers
- 3.1 Global Hyperthermia Therapy for Cancer Revenue by Manufacturers (2021-2026)
- 3.2 Global Hyperthermia Therapy for Cancer Sales by Manufacturers (2021-2026)
- 3.3 Global Hyperthermia Therapy for Cancer Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Hyperthermia Therapy for Cancer Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Hyperthermia Therapy for Cancer Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Hyperthermia Therapy for Cancer Manufacturers, Product Type & Application
- 3.7 Global Hyperthermia Therapy for Cancer Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Hyperthermia Therapy for Cancer Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Hyperthermia Therapy for Cancer Players Market Share by Revenue in 2025
- 3.8.3 2025 Hyperthermia Therapy for Cancer Tier 1, Tier 2, and Tier 3
4 Hyperthermia Therapy for Cancer Market by Type
- 4.1 Hyperthermia Therapy for Cancer Type Introduction
- 4.1.1 Superficial Hyperthermia
- 4.1.2 Deep Regional Hyperthermia
- 4.2 Global Hyperthermia Therapy for Cancer Sales by Type
- 4.2.1 Global Hyperthermia Therapy for Cancer Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Hyperthermia Therapy for Cancer Sales by Type (2021-2032)
- 4.2.3 Global Hyperthermia Therapy for Cancer Sales Market Share by Type (2021-2032)
- 4.3 Global Hyperthermia Therapy for Cancer Revenue by Type
- 4.3.1 Global Hyperthermia Therapy for Cancer Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Hyperthermia Therapy for Cancer Revenue by Type (2021-2032)
- 4.3.3 Global Hyperthermia Therapy for Cancer Revenue Market Share by Type (2021-2032)
5 Hyperthermia Therapy for Cancer Market by Application
- 5.1 Hyperthermia Therapy for Cancer Application Introduction
- 5.1.1 Breast Cancer
- 5.1.2 Cervical Cancer
- 5.1.3 Soft Tissue Sarcoma
- 5.1.4 Melanoma
- 5.1.5 Others
- 5.2 Global Hyperthermia Therapy for Cancer Sales by Application
- 5.2.1 Global Hyperthermia Therapy for Cancer Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Hyperthermia Therapy for Cancer Sales by Application (2021-2032)
- 5.2.3 Global Hyperthermia Therapy for Cancer Sales Market Share by Application (2021-2032)
- 5.3 Global Hyperthermia Therapy for Cancer Revenue by Application
- 5.3.1 Global Hyperthermia Therapy for Cancer Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Hyperthermia Therapy for Cancer Revenue by Application (2021-2032)
- 5.3.3 Global Hyperthermia Therapy for Cancer Revenue Market Share by Application (2021-2032)
6 Global Hyperthermia Therapy for Cancer Sales by Region
- 6.1 Global Hyperthermia Therapy for Cancer Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Hyperthermia Therapy for Cancer Sales by Region (2021-2032)
- 6.2.1 Global Hyperthermia Therapy for Cancer Sales by Region (2021-2026)
- 6.2.2 Global Hyperthermia Therapy for Cancer Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Hyperthermia Therapy for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Hyperthermia Therapy for Cancer Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Hyperthermia Therapy for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Hyperthermia Therapy for Cancer Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Hyperthermia Therapy for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Hyperthermia Therapy for Cancer Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Hyperthermia Therapy for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Hyperthermia Therapy for Cancer Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Hyperthermia Therapy for Cancer Revenue by Region
- 7.1 Global Hyperthermia Therapy for Cancer Revenue by Region
- 7.1.1 Global Hyperthermia Therapy for Cancer Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Hyperthermia Therapy for Cancer Revenue by Region (2021-2026)
- 7.1.3 Global Hyperthermia Therapy for Cancer Revenue by Region (2027-2032)
- 7.1.4 Global Hyperthermia Therapy for Cancer Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Hyperthermia Therapy for Cancer Revenue (2021-2032)
- 7.2.2 North America Hyperthermia Therapy for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Hyperthermia Therapy for Cancer Revenue (2021-2032)
- 7.3.2 Europe Hyperthermia Therapy for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Hyperthermia Therapy for Cancer Revenue (2021-2032)
- 7.4.2 Asia-Pacific Hyperthermia Therapy for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Hyperthermia Therapy for Cancer Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Hyperthermia Therapy for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Pyrexar Medical
- 8.1.1 Pyrexar Medical Company Information
- 8.1.2 Pyrexar Medical Business Overview
- 8.1.3 Pyrexar Medical Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Pyrexar Medical Hyperthermia Therapy for Cancer Product Portfolio
- 8.1.5 Pyrexar Medical Recent Developments
- 8.2 Oncotherm
- 8.2.1 Oncotherm Company Information
- 8.2.2 Oncotherm Business Overview
- 8.2.3 Oncotherm Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Oncotherm Hyperthermia Therapy for Cancer Product Portfolio
- 8.2.5 Oncotherm Recent Developments
- 8.3 Andromedic
- 8.3.1 Andromedic Company Information
- 8.3.2 Andromedic Business Overview
- 8.3.3 Andromedic Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Andromedic Hyperthermia Therapy for Cancer Product Portfolio
- 8.3.5 Andromedic Recent Developments
- 8.4 Yamamoto Vinita
- 8.4.1 Yamamoto Vinita Company Information
- 8.4.2 Yamamoto Vinita Business Overview
- 8.4.3 Yamamoto Vinita Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Yamamoto Vinita Hyperthermia Therapy for Cancer Product Portfolio
- 8.4.5 Yamamoto Vinita Recent Developments
- 8.5 Med-Logix
- 8.5.1 Med-Logix Company Information
- 8.5.2 Med-Logix Business Overview
- 8.5.3 Med-Logix Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Med-Logix Hyperthermia Therapy for Cancer Product Portfolio
- 8.5.5 Med-Logix Recent Developments
- 8.6 Thermofield
- 8.6.1 Thermofield Company Information
- 8.6.2 Thermofield Business Overview
- 8.6.3 Thermofield Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Thermofield Hyperthermia Therapy for Cancer Product Portfolio
- 8.6.5 Thermofield Recent Developments
- 8.7 Celsius42
- 8.7.1 Celsius42 Company Information
- 8.7.2 Celsius42 Business Overview
- 8.7.3 Celsius42 Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Celsius42 Hyperthermia Therapy for Cancer Product Portfolio
- 8.7.5 Celsius42 Recent Developments
- 8.8 Dongseo Medicare
- 8.8.1 Dongseo Medicare Company Information
- 8.8.2 Dongseo Medicare Business Overview
- 8.8.3 Dongseo Medicare Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Dongseo Medicare Hyperthermia Therapy for Cancer Product Portfolio
- 8.8.5 Dongseo Medicare Recent Developments
- 8.9 ThermaSolutions
- 8.9.1 ThermaSolutions Company Information
- 8.9.2 ThermaSolutions Business Overview
- 8.9.3 ThermaSolutions Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 ThermaSolutions Hyperthermia Therapy for Cancer Product Portfolio
- 8.9.5 ThermaSolutions Recent Developments
- 8.10 Verthermia
- 8.10.1 Verthermia Company Information
- 8.10.2 Verthermia Business Overview
- 8.10.3 Verthermia Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Verthermia Hyperthermia Therapy for Cancer Product Portfolio
- 8.10.5 Verthermia Recent Developments
- 8.11 Combat Medical
- 8.11.1 Combat Medical Company Information
- 8.11.2 Combat Medical Business Overview
- 8.11.3 Combat Medical Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Combat Medical Hyperthermia Therapy for Cancer Product Portfolio
- 8.11.5 Combat Medical Recent Developments
- 8.12 Hydrosun
- 8.12.1 Hydrosun Company Information
- 8.12.2 Hydrosun Business Overview
- 8.12.3 Hydrosun Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Hydrosun Hyperthermia Therapy for Cancer Product Portfolio
- 8.12.5 Hydrosun Recent Developments
- 8.13 RanD Biotech
- 8.13.1 RanD Biotech Company Information
- 8.13.2 RanD Biotech Business Overview
- 8.13.3 RanD Biotech Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 RanD Biotech Hyperthermia Therapy for Cancer Product Portfolio
- 8.13.5 RanD Biotech Recent Developments
- 8.14 Shenzhen ET Medical Technology
- 8.14.1 Shenzhen ET Medical Technology Company Information
- 8.14.2 Shenzhen ET Medical Technology Business Overview
- 8.14.3 Shenzhen ET Medical Technology Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Shenzhen ET Medical Technology Hyperthermia Therapy for Cancer Product Portfolio
- 8.14.5 Shenzhen ET Medical Technology Recent Developments
- 8.15 Jiangsu Nova Medical Equipment
- 8.15.1 Jiangsu Nova Medical Equipment Company Information
- 8.15.2 Jiangsu Nova Medical Equipment Business Overview
- 8.15.3 Jiangsu Nova Medical Equipment Hyperthermia Therapy for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Jiangsu Nova Medical Equipment Hyperthermia Therapy for Cancer Product Portfolio
- 8.15.5 Jiangsu Nova Medical Equipment Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Hyperthermia Therapy for Cancer Value Chain Analysis
- 9.1.1 Hyperthermia Therapy for Cancer Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Hyperthermia Therapy for Cancer Production Mode & Process
- 9.2 Hyperthermia Therapy for Cancer Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Hyperthermia Therapy for Cancer Distributors
- 9.2.3 Hyperthermia Therapy for Cancer Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst